Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company specializing in modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Stock Impact - On April 15, 2025, Simulations Plus hired Grant Thornton LLP as its new auditor, which was followed by a significant stock price drop after the company announced disappointing preliminary financial results for Q3 2025 on June 11, 2025, with a decline of over 24% from $26.44 to $20.05 per share [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results on July 14, 2025, and subsequently dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Auditor Dispute - Grant Thornton disagreed with Simulations Plus's characterizations regarding internal controls and reporting, leading to further stock price decline of nearly 26% from $17.47 to $12.97 per share following the announcement of the impairment charge and auditor findings [5].

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but the Conestoga Small Cap Composite underperformed the Russell 2000 Growth Index, returning -1.4% compared to the Index's 12.2% gain [1] - The gains in the Russell 2000 Growth Index were primarily driven by low-quality stocks, particularly unprofitable, high-beta names [1] Company Analysis: Simulations Plus, Inc. (NASDAQ:SLP) - Simulations Plus, Inc. specializes in drug discovery and development software that leverages AI and machine learning for modeling and simulation [2] - The stock had a one-month return of 0.98% but experienced a significant decline of 54.90% over the past 52 weeks, closing at $15.40 per share with a market capitalization of $309.957 million on October 17, 2025 [2] - The company has faced slowing revenue growth due to funding pressures on smaller biotech customers, which has reduced demand for its products [3] - Despite its potential, the valuation of Simulations Plus remains elevated compared to peers, raising concerns about risk/reward dynamics [3] - Increased competition in drug-modeling software and inconsistent performance in consulting services may further pressure the company's margins [3] - Conestoga Capital Advisors decided to sell the stock due to near-term headwinds outweighing long-term potential [3] Hedge Fund Interest - Simulations Plus, Inc. was held by 11 hedge fund portfolios at the end of Q2 2025, a decrease from 13 in the previous quarter [4] - While acknowledging the potential of Simulations Plus, the company believes that other AI stocks present greater upside potential with less downside risk [4]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and indicated ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor, Grant Thornton, due to unresolved matters regarding segment reporting and internal controls [5] - Following the impairment charge and auditor dismissal, the stock price fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1 - The investigation is focused on the potential impact of misleading information on Simulations Plus shareholders [1] - Shareholders who purchased Simulations Plus securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor's Findings - Grant Thornton identified unresolved issues regarding segment reporting and internal controls, which contradicted Simulations Plus's statements about its financial reporting [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings in June 2024, aiming to double its total addressable market and enhance sales [2][3]. Financial Reporting Issues - Simulations Plus claimed effective internal controls over financial reporting; however, it appears the company struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, which later raised concerns regarding the company's financial reporting [4][5]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025 on June 11, 2025, Simulations Plus's stock price dropped by over 24%, from $26.44 to $20.05 per share [4]. - The company reported a $77.2 million charge related to prior acquisitions on July 14, 2025, leading to a further decline in stock price by nearly 26%, from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears there were struggles with the integration of Pro-ficiency and deficiencies in internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor Dismissal - The dismissal of Grant Thornton was linked to unresolved issues regarding segment reporting and internal controls, which the auditor communicated to management and the Audit Committee [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Simulations Plus, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The law firm is reaching out to Simulations Plus stockholders who may have suffered losses and encourages them to discuss their legal rights [1][3]. Financial Performance - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million [6]. - The company experienced a net loss of $67.3 million and a diluted loss per share of $3.35, which included a non-cash impairment charge of $77.2 million, contrasting with a net income of $3.1 million and diluted earnings per share of $0.15 for the same period in 2024 [6]. - The fiscal 2025 adjusted earnings guidance was revised down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [6]. Stock Market Reaction - Following the financial results announcement, Simulations Plus's stock price fell by $4.50 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [6]. Company Restructuring - In June, Simulations Plus initiated a restructuring of its operations, which included workforce reductions and cost-cutting measures aimed at improving operational efficiency and reducing expenses [6].

Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial disclosures and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition and Integration Issues - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., claiming the acquisition would double its total addressable market and significantly contribute to sales [2][3]. - However, the company appears to have struggled with the integration of Pro-ficiency and lacked effective internal controls over financial reporting [3]. Financial Performance and Stock Impact - On June 11, 2025, Simulations Plus announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 results, and subsequently dismissed its auditor, Grant Thornton, due to unresolved issues regarding segment reporting and internal controls [5]. - Following these revelations, the stock price fell nearly 26% from $17.47 to $12.97 per share [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Simulations Plus, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The law firm is reaching out to Simulations Plus stockholders who may have suffered losses and encourages them to discuss their legal rights [1][3]. Financial Performance - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million [6]. - The company experienced a net loss of $67.3 million and a diluted loss per share of $3.35, which included a non-cash impairment charge of $77.2 million, compared to a net income of $3.1 million and diluted earnings per share of $0.15 for the same period in 2024 [6]. - The fiscal 2025 adjusted earnings guidance was revised down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [6]. Operational Changes - In June, Simulations Plus initiated a restructuring of its operations, which included workforce reductions and cost-cutting measures aimed at improving operational efficiency and reducing expenses [6]. Stock Market Reaction - Following the financial results announcement, Simulations Plus's stock price fell by $4.50 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [6].